Arterial hypertension is a leading cause of death globally. Due to ageing, the rising
incidence of obesity, and socioeconomic and environmental changes, its incidence …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Cardiovascular disease accounts for more than 17 million deaths globally every year, of
which complications of hypertension account for 9.4 million deaths worldwide. Early …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Heart failure (HF) treatment has changed substantially over the last 30 years, leading to
significant reductions in mortality and hospital admissions in patients with HF with reduced …

Hypertension is a common pathological condition predisposing to a higher occurrence of
cardiovascular diseases and events. Unfortunately, treatment of hypertension is still …

Introduction Hypertension is a significant risk factor in heart failure for worldwide patients.
More than half of hypertensive patients suffer from heart failure. Recently, sacubitril/valsartan …

Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with
multifaceted pathophysiology. All approaches to neurohormonal modulation were shown not …

LCZ696 blocks both angiotensin receptor type 1 (ATR1) and neprilysin (NEP), which are
intricate in the degradation of natriuretic peptides (NPs) and other endogenous peptides. It …

Aim Sacubitril/valsartan has been demonstrated to reduce blood pressure in hypertensive
patients, but the best dose remains unclear. We performed this network meta-analysis to …